Women still represent a minority of entrepreneurs globally, but we are fortunate that Dr. Mengchu Wu brought together a group of passionate scientists, engineers, and business professionals to boldly revolutionize metagenomic next-generation sequencing.
Dr. Wu began her career in biochemistry by earning her Ph.D. in Biomedical Sciences from the University of Massachusetts Chan Medical School. She co-authored more than 20 peer-reviewed papers including those published in Nature, Cell Stem Cell, Genome Biol., Nucl. Acids Res. Since then, she has held Chief Technology and Chief Executive Officer roles at various biotechnology companies before co-discovering the zwitterionic membrane for host cell depletion in metagenomic next-generation sequencing (mNGS). From there, she launched Micronbrane Medical to guide the development of innovations that reduce the time, complexity, and cost of mNGS. Consequently, the company provides a suite of mNGS-based products that optimize the entire mNGS workflow and support a growing number of research, clinical, and industrial applications.
Co-Founder, CEO and Chairwoman
Dr. Mengchu Wu is a visionary leader with extensive experience in healthcare and biotechnology. Before co-founding Micronbrane Medical, Mengchu was CEO and CTO at Health GeneTech. Her career also encompassed engineering and application development roles at Personal Genomics and Vela Diagnostics. Prior to that, she was a Research Fellow at the National University of Singapore. Mengchu is a distinguished alumna of University of Massachusetts, Chan Medical School, earning her Ph.D. in Biomedical Sciences, and a B.S. in Biochemistry, from Fudan University.
Co-Founder
Dr. Hau Hung’s diverse experience and academic achievements have equipped him with a unique perspective that drives innovation and operational precision. His previous roles include Operations Manager at Kingmax Inc., Sales Manager at Bio-REV, and Scientist at Merck. He has conducted research at prestigious institutions, including the National University of Singapore, Fred Hutchinson Cancer Research Center, and UMass Chan Medical School.
CFO
Eric brings over 30 years of financial management expertise to the company after making a significant impact in the semiconductor industry, serving as the finance director and spokesperson at KingMax, Inc. Prior to that, Eric held progressive financial roles at an automotive safety assistance system (ADAS) image sensing IC packaging company, handling finance, accounting, taxation, and strategic planning for mergers, acquisitions, and reinvestments. Eric holds an Executive Master of Business Administration from the National Tsing Hua University. His wealth of experience and strategic mindset shapes Micronbrane Medical’s financial success.
CMO
Kristi Ashton is a seasoned marketing executive with a career spanning 25 years. She holds an Executive MBA in Digital Marketing, an Interdisciplinary M.S. in Engineering, Business, and Law and a B.S in Biology. Kristi has held key leadership positions, including Head of Marketing at Gencove and Director of Digital Marketing at Guardant Health, and Associate Director of Digital Marketing at J&J, delivering substantial results and driving growth in the life science sector.
Micronbrane Medical technologies enrich our understanding of microorganisms through innovative metagenomic collection devices, novel host depletion, mNGS-grade reagents, advanced metagenomic sequencing assays, automation instrumentation, plus rapid bioinformatic software.
© 2024 Micronbrane Medical
